



Attorney Docket No. Le A 34 491

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Lerchen, et al.

Group No.: 1625

Serial No.: 10/026,237

Examiner:

Filed: 12/21/2001

For: "Cytostatic-Glycoconjugates Having Specifically Cleavable Linking Units"

1000 #5
PATENT
RECEIVED
AUG 07 2002
TECH CENTER 1600/2900

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: AUG 01 2002

Muriellen Chapdelaine
Signature of Person Certifying

**ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231**

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.


Respectfully submitted,

Reg. No. 48,972

Telephone: (203) 812-6450

Date: 8/1/02

Susan M. Pellegrino
Susan M. Pellegrino
Attorney for Applicant(s)
Bayer Corporation
400 Morgan Lane
West Haven, CT 06516

Form PTO-1449 (Modified)	 U.S. Department of Commerce Patent and Trademark Office	Serial No. 10/026,237	Group Art Unit 1625	Filing Date 12/21/2001	Atty. Docket No. LeA00191
		Applicant(s) Lerchen, et al.			

INFORMATION DISCLOSURE CITATION



RECEIVED
AUG 07 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

*		DOCUMENT NO.							DATE MM/DD/YY	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	U1	4	9	4	3	5	7	9	07/24/90	Vishnuvajjala, et al.	514	283	10/06/87
	U2	4	9	8	0	3	4	3	12/25/90	Stella, et al.	514	18	06/20/89
	U3	4	7	5	7	0	7	2	07/12/88	Kabbe, et al.	514	257	03/17/87
	U4	4	9	7	5	2	7	8	12/04/90	Senter, et al.	424	94.3	06/29/88
	U5	5	9	5	5	1	0	0	09/21/99	Bosslet, et al.	424	450	05/24/95
	U6	5	4	6	4	7	9	6	11/07/95	Peterson, et al.	514	312	06/11/92
	U7	5	5	6	1	1	1	9	10/01/96	Jacquesy, et al.	514	34	05/27/94
	U8	6	2	7	1	3	4	2	08/07/01	Lerchen, et al.	530	322	09/25/97

FOREIGN PATENT DOCUMENTS														
		DOCUMENT NO.							DATE DD/MM/YY	COUNTRY	PRIMARY CLASS	SUB-CLASS	TRANSLATION	
													YES	NO
/	F1	9	8	1	5	5	7	1	16/04/98	WO				
/	F2	9	8	1	5	5	7	3	16/04/98	WO				
/	F3	9	6	0	2	5	4	6	01/02/96	WO				
/	F4	8	8	0	7	3	7	8	06/10/88	WO				

EXAMINER	DATE CONSIDERED
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



✓	F5	9	8	5	1	7	0	3	19/11/98	WO				
✓	F6	9	8	1	4	4	6	8	09/04/98	WO				
✓	F7	0	5	9	5	1	3	3	04/05/94	EP				
✓	F8	4	2	3	6	2	3	7	28/04/94	DE				
✓	F9	0	5	1	1	9	1	7	29/04/92	EP				
✓	F10	0	5	2	0	2	4	0	30/12/92	EP				
✓	F11	0	5	0	1	2	5	0	02/09/92	EP				
✓	F12	4	2	2	9	9	0	3	10/03/94	DE				
✓	F13	9	8	1	4	4	5	9	09/04/98	WO				
✓	F14	9	6	0	0	5	0	3	11/01/96	WO				
✓	F15	4	2	5	3	9	7	3	09/09/92	JP				
✓	F16	9	6	3	1	5	3	2	10/10/96	WO				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

R1	Gabius, J., "Endogene Lektine in Tumoren und ihre Mogliche Bedeutung fur Diagnose und Therapie Von Krebserkrankungen", <i>Onkologie</i> , <u>12</u> : 175-181 (April, 1989)
R2	Wall, M., Wani, M., Cook, C., Palmer, K., McPhail, A., Sim, G., "Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca Acuminata", <i>J. Amer. Chem. Soc.</i> , <u>88</u> : 3888-3890 (Aug. 1966)
R3	Jansen, R., Molema, G., Ching, T., Oosting, R., Harms, G., Moolenaar, F., Hardonk, M., Meijer, D., "Hepatic Endocytosis of Various Types of Mannose-terminated Albumins", <i>J. of Biol. Chem.</i> , <u>266</u> : 3343-3348 (1991)
R4	Haltiwanger, R., Lehrman, M., Eckhardt, A., Hill, R., "The Distribution and Localization of the Fucose-Binding Lectin in Rat Tissues and the Identification of a High Affinity Form of the Mannose/N-Acetylglucosamine-Binding Lectin in Rat Liver", <i>J. Biol. Chem.</i> , <u>261</u> : 7433-7439 (1986)
R5	Aminoff, D., Bruegge, W., Bell, W., Sarpolis, K., Williams, R., "Role of Sialic Acid in Survival of Erythrocytes in the Circulation: Interaction of Neuraminidase-Treated and Untreated Erythrocytes with Spleen and Liver at the Cellular Level", <i>Proc. Natl. Acad. Sci., USA</i> , <u>74</u> : 1521-1524 (April, 1977)
R6	Ashwell, G., Harford, J., "Carbohydrate-Specific Receptors of the Liver", <i>Ann. Rev. Biochem.</i> , <u>51</u> : 531-534 (1982)
R7	Denmeade, S., Lou, W., Lovgren, J., Malm, J., Lilja, H., Isaacs, J., "Specific and Efficient Peptide Substrates for Assaying the Proteolytic Activity of Prostate-Specific Antigen", <i>Cancer Research</i> , <u>57</u> : 4924-4930 (Nov., 1997)

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



R8	Ratnikov, B., Deryugina, E., Leng, J., Marchenko, G., Dembrow, D., Strongin, A., "Determination of Matrix Metalloproteinase Activity Using Biotinylated Gelatin", <i>Anal. Biochem.</i> , <u>286</u> : 149-155 (2000)
R9	Lark, M., Williams, H., Hoernner, L., Weidner, J., Ayala, J., Harper, C., Christen, A., Olszewski, J., Konteatis, Z., Webbers, R., Mumford, R., "Quantification of a Matrix Metalloproteinase-Generated Aggrecan G1 Fragment Using Monospecific Anti-Peptide Serum", <i>Biochem. J.</i> , <u>307</u> : 245-252 (1995)
R10	Xia, T., Akers, K., Eisen, A., Seltzer, J., "Comparison of Cleavage Site Specificity of Gelatinases A and B Using Collagenous Peptides", <i>Biochem. Biophys. Acta</i> , <u>1293</u> : 259-266 (1996)
R11	Peng, K., Morling, F., Cosset, F., Murphy, G., Russell, S., "A Gene Delivery System Activatable by Disease-Associated Matrix Metalloproteinases", <i>Human Gene Ther.</i> , <u>8</u> : 729-738 (April, 1997)
R12	O'Farrell, T., Pourmotabbed, T., "The Fibronectin-Like Domain Is Required for The Type V and XI Collagenolytic Activity of Gelatinase B", <i>Archives of Biochem. And Biophysics</i> , <u>354</u> : 24-30 (June, 1998)
R13	Timar, F., Botyanszki, J., Suli-Vargha, H., Babo, I., Olah, J., Pogany, G., Jeney, A., "The Antiproliferative Action of a Melphalan Hexapeptide With Collagenase-Cleavable Site", <i>Cancer Chemother. Pharmacol.</i> , <u>41</u> : 292-298 (1998)
R14	Nogusa, H., Yano, T., Kashima, N., Yamamoto, K., Okuno, S., Hamana, H., "Structure-Activity Relationships of Carboxymethylpullulan-Peptide-Doxorubicin Conjugates - Systematic Modification of Peptide Spacers", <i>Bioorgan. & Med. Chem. Letters</i> , <u>10</u> : 227-230 (2000)

RECEIVED
AUG 07 2002
PATENT CENTER 1600/2900

EXAMINER	DATE CONSIDERED
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	